Kindly MD (NAKA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 17.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 4.41
• Revenue Growth: -27.67%
• EPS Growth: -110.06%
• Country: US
• Employees: 23
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 376,146,060
• 10 Day Avg. Volume: 44,985,479
• 30 Day Avg. Volume: 17,568,781
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 1.36
• Enterprise Value/Gross Profit: 1.37
• Enterprise Value/Ebitda: -0.58
• 1Y Price Target: $8.00
• Price Target Upside: 595.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 39 Underperform
• Price Target: $1.50 ▲(30.43% Upside)

The overall stock score of 39 reflects significant financial challenges, bearish technical indicators, and poor valuation metrics. The company's negative profitability and reliance on financing activities raise concerns about its financial health. The technical analysis indicates a bearish trend, and the lack of earnings call and corporate events data limits further insights.

Positive Factors

Business Model

The subscription-based model for telemedicine and chronic disease management provides a stable revenue stream, enhancing predictability and resilience in revenue generation.

Gross Profit Margin

A high gross profit margin indicates strong pricing power and cost control, which can support long-term profitability if operational efficiencies improve.

Equity Ratio Improvement

Improved equity ratio suggests better asset financing through equity, enhancing financial stability and reducing reliance on debt.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in market demand or competitive positioning, which could impact long-term growth prospects.

Negative Profitability

Negative net profit margin reflects operational inefficiencies and challenges in achieving profitability, which could hinder sustainable growth.

Cash Flow Issues

Negative free cash flow indicates cash management struggles, potentially limiting the company's ability to invest in growth and innovation.

Kindly MD Business Overview & Revenue Model

Company Description

Kindly MD, Inc., a healthcare and healthcare data company, provides direct health care services to patients integrating prescription medicine and behavioral health services. The company offers specialty outpatient clinical services based on a subscription and fee-for-service basis to augment traditional healthcare. It provides evaluation and management services, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support, overdose education, peer support, limited urgent care, preventative medicine, travel, and hormone therapy; and data collection and research, and online and email campaign marketing services, as well as engages in the retail sale of health care products through clinics and online. Kindly MD, Inc. was formerly known as Utah Therapeutic Health Center, LLC and changed its name to Kindly MD, Inc. in March 2022. The company was incorporated in 2019 and is based in Salt Lake City, Utah.

How the Company Makes Money

Kindly MD generates revenue primarily through service fees charged for its telemedicine consultations and chronic disease management programs. These services are often offered on a subscription basis, providing a consistent revenue stream. Additionally, Kindly MD may partner with healthcare providers and insurance companies to expand its service offerings and reach more patients, which can also contribute to its earnings through collaborative agreements and shared revenue models.

Kindly MD Financial Statement Overview

Summary

Kindly MD, Inc. is facing significant financial challenges, with declining revenues and profitability issues. Although the balance sheet shows some stability with a moderate debt level, negative equity in 2023 and reliance on financing raise concerns. Cash flow struggles highlight the need for better operational efficiency and cost management to improve financial health.

Income Statement

Kindly MD, Inc. has faced significant challenges in revenue and profit growth. The Gross Profit Margin remains high at 96.95% for 2024, but the Net Profit Margin is negative at -133.00%, indicating substantial losses. The company has faced revenue decline from the previous year, further exacerbating its profitability issues. The negative EBIT and EBITDA margins highlight operational inefficiencies and the need for cost management.

Balance Sheet

The company's Debt-to-Equity Ratio is 0.31, indicating a moderate level of leverage. However, the negative equity in 2023 raises concerns about financial stability. The Return on Equity is not meaningful due to negative equity in 2023, but the Equity Ratio improved to 69.82% in 2024, reflecting better asset financing through equity.

Cash Flow

Cash flow analysis shows a negative Free Cash Flow of -$3.09 million in 2024, indicating cash management struggles. The Operating Cash Flow to Net Income Ratio is negative, reflecting inefficiencies in converting income into cash. The company heavily relies on financing activities to support its cash needs, which may not be sustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.24M	2.72M	3.77M	3.79M	2.50M
Gross Profit	2.21M	2.64M	-264.17K	-595.29K	914.92K
EBITDA	-5.23M	-3.00M	-1.36M	-2.42M	124.74K
Net Income	-5.47M	-3.62M	-1.62M	-2.54M	149.34K
Balance Sheet
Total Assets	9.89M	3.68M	1.10M	947.00K	447.64K
Cash, Cash Equivalents and Short-Term Investments	6.02M	2.27M	525.50K	186.92K	94.69K
Total Debt	559.02K	783.68K	636.38K	391.13K	109.81K
Total Liabilities	923.39K	1.11M	1.21M	565.98K	174.56K
Stockholders Equity	8.97M	2.57M	-108.41K	381.01K	273.09K
Cash Flow
Free Cash Flow	-5.98M	-3.09M	-463.91K	-457.77K	57.84K
Operating Cash Flow	-5.59M	-3.07M	-449.49K	-140.38K	121.44K
Investing Cash Flow	-3.09M	-401.63K	-14.42K	-317.39K	-63.60K
Financing Cash Flow	8.82M	5.22M	802.49K	550.00K	-45.34K

Kindly MD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAKA, the sentiment is Negative. The current price of 1.15 is below the 20-day moving average (MA) of 2.95, below the 50-day MA of 7.12, and below the 200-day MA of 6.22, indicating a bearish trend. The MACD of -1.93 indicates Negative momentum. The RSI at 33.96 is Neutral, neither overbought nor oversold. The STOCH value of 10.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAKA.

Kindly MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BTSG	76 Outperform	$4.85B	92.66	3.76%	―	20.60%	―
AS	69 Neutral	$19.10B	83.77	1.45%	―	22.86%	―
AUNA	69 Neutral	$492.93M	7.72	14.44%	―	2.83%	―
CORZ	49 Neutral	$5.15B	-29.47	101.15%	―	-39.43%	90.95%
NAKA	39 Underperform	―	―	-81.92%	―	-27.67%	-110.06%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

Kindly MD Corporate Events

Kindly MD Announces Debenture Redemption Plan

On September 15, 2025, Kindly MD, Inc. announced its intention to redeem its Secured Convertible Debenture issued on August 15, 2025. The redemption, scheduled for September 29, 2025, will involve a cash payment of 100% of the outstanding principal plus a 1.5% premium, totaling $203,000,000 if not converted by the holder. This move indicates a strategic financial decision by the company, potentially impacting its financial structure and stakeholder relations.

The most recent analyst rating on (NAKA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Kindly MD stock, see the NAKA Stock Forecast page.

Kindly MD Files Form S-3, Highlights Bitcoin Strategy

On September 15, 2025, Kindly MD, Inc. informed shareholders about filing a Form S-3 on September 12, 2025, which may lead to increased share price volatility. The company emphasized its commitment to its long-term vision and highlighted its strategy to build a Bitcoin-denominated treasury and invest in Bitcoin-focused companies. Kindly MD has achieved significant milestones, including raising $742 million, establishing a 5,700+ BTC treasury, and launching a $5 billion ATM program. The company aims to capitalize on Bitcoin’s mainstream acceptance and expand access to Bitcoin through publicly-traded Bitcoin treasury companies, ultimately enhancing liquidity and shareholder value.

The most recent analyst rating on (NAKA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Kindly MD stock, see the NAKA Stock Forecast page.

Kindly MD’s Subsidiary Invests in Metaplanet Inc.

On September 9, 2025, KindlyMD’s subsidiary, Nakamoto Holdings, committed to investing up to $30 million in Metaplanet Inc.’s international equity financing. This marks Nakamoto’s largest single investment and its first in an Asian public company with a Bitcoin treasury strategy. The investment aims to support Metaplanet’s efforts to accelerate Bitcoin accumulation and expand its net asset value, with the funding expected on September 16, 2025. The transaction underscores KindlyMD’s strategic focus on integrating Bitcoin into global capital markets, enhancing its positioning in the Bitcoin and healthcare industries.

The most recent analyst rating on (NAKA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Kindly MD stock, see the NAKA Stock Forecast page.